Restricted accessResearch articleFirst published online 2023-04-04
Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer’s Disease: A Cross-Sectional Study
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme in the formation of amyloid-β (Aβ) protein. Increasing evidence suggests that BACE1 concentration is a potential biomarker for Alzheimer’s disease (AD).
Objective:
To evaluate the correlations between plasma BACE1 concentration, cognition, and hippocampal volume at different stages of the AD continuum.
Methods:
Plasma BACE1 concentrations were measured in 32 patients with probable dementia due to AD (ADD), 48 patients with mild cognitive impairment (MCI) due to AD, and 40 cognitively unimpaired (CU) individuals. Memory function was evaluated using the auditory verbal learning test (AVLT), and voxel-based morphometry was used to analyze bilateral hippocampal volumes. Correlation and mediation analyses were performed to investigate the associations between plasma BACE1 concentration, cognition, and hippocampal atrophy.
Results:
The MCI and ADD groups exhibited elevated BACE1 concentrations compared with the CU group after adjusting for age, sex, and apolipoprotein E (APOE) genotype. Increased BACE1 concentration was found in AD continuum patients who were APOE ɛ4 carriers (p < 0.05). BACE1 concentration was negatively associated with the scores of the subitems of the AVLT and hippocampal volume (p < 0.05, false discovery rate correction) in the MCI group. Moreover, bilateral hippocampal volume mediated the relationship between BACE1 concentration and recognition in the MCI group.
Conclusion:
BACE1 expression increased in the AD continuum, and bilateral hippocampal volume mediated the effect of BACE1 concentration on memory function in patients with MCI. Research has indicated that the plasma BACE1 concentration might be a biomarker at the early stage of AD.
JackCRJr, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
5.
VassarR (2004) BACE1: The beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci23, 105–114.
6.
HampelH, VassarR, De StrooperB, HardyJ, WillemM, SinghN, ZhouJ, YanR, VanmechelenE, De Vos A, NisticòR, CorboM, ImbimboBP, StrefferJ, VoytyukI, TimmersM, Tahami Monfared AA, IrizarryM, AlbalaB, KoyamaA, WatanabeN, KimuraT, YarenisL, ListaS, KramerL, VergalloA (2021) The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry89, 745–756.
7.
LuoY, BolonB, KahnS, BennettBD, Babu-KhanS, DenisP, FanW, KhaH, ZhangJ, GongY, MartinL, LouisJC, YanQ, RichardsWG, CitronM, VassarR (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci4, 231–232.
8.
DominguezD, TournoyJ, HartmannD, HuthT, CrynsK, DeforceS, SerneelsL, CamachoIE, MarjauxE, CraessaertsK, RoebroekAJ, SchwakeM, D’HoogeR, BachP, KalinkeU, MoecharsD, AlzheimerC, ReissK, SaftigP, De Strooper B (2005) Phenotypic and biochemicalanalyses of BACE1- and BACE2-deficient mice., J Biol Chem280, 30797–30806.
9.
ShenY, WangH, SunQ, YaoH, KeeganAP, MullanM, WilsonJ, ListaS, LeyheT, LaskeC, RujescuD, LeveyA, WallinA, BlennowK, LiR, HampelH (2018) Increased plasma beta-secretase 1 may predict conversion to Alzheimer’s disease dementia in individuals with mild cognitive impairment. Biol Psychiatry83, 447–455.
10.
VergalloA, HouotM, CavedoE, LemercierP, VanmechelenE, De Vos A, HabertMO, PotierMC, DuboisB, ListaS, HampelH (2019) Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimers Dement15, 1274–1285.
11.
WuG, SankaranarayananS, WongJ, TugushevaK, MichenerMS, ShiX, CookJJ, SimonAJ, SavageMJ (2012) Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease. J Neurosci Res90, 2247–2258.
12.
SchipkeCG, De VosA, FuentesM, JacobsD, VanmechelenE, PetersO (2018) Neurogranin and BACE1 in CSF as potential biomarkers differentiating depression with cognitive deficits from early Alzheimer’s disease: A pilot study. Dement Geriatr Cogn Dis Extra8, 277–289.
13.
ZhongZ, EwersM, TeipelS, BürgerK, WallinA, BlennowK, HeP, McAllisterC, HampelH, ShenY (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry64, 718–726.
14.
SavageMJ, HolderDJ, WuG, KaplowJ, SiuciakJA, PotterWZ (2015) Soluble BACE-1 activity and sAβPPβ concentrations in Alzheimer’s disease and age-matched healthy control cerebrospinal fluid from the Alzheimer’s Disease Neuroimaging Initiative-1 Baseline Cohort. J Alzheimers Dis46, 431–440.
15.
ManzinePR, SouzaMDS, CominettiMR (2016) BACE1 levels are increased in plasma of Alzheimer’s disease patients compared with matched cognitively healthy controls. Per Med13, 531–540.
16.
EwersM, ZhongZ, BürgerK, WallinA, BlennowK, TeipelSJ, ShenY, HampelH (2008) Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer’s disease. Brain131, 1252–1258.
ZhangM, ZhongX, ShiH, VanmechelenE, De Vos A, LiuS, ChenB, MaiN, PengQ, ChenX, WuZ, HouL, ZhouH, OuyangC, ZhangW, LiangW, DaiC, NingY (2020) BACE1 and other Alzheimer’s-related biomarkers in cerebrospinal fluid and plasma distinguish Alzheimer’s disease patients from cognitively-impaired neurosyphilis patients. J Alzheimers Dis77, 313–322.
19.
MarshallGA, LoriusN, LocascioJJ, HymanBT, RentzDM, JohnsonKA, SperlingRA (2014) Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer’s disease spectrum, J Alzheimers Dis41, 719–728.
20.
MattssonN, InselPS, AisenPS, JagustW, MackinS, WeinerM (2015) Brain structure and function as mediators of the effects of amyloidon memory. Neurology84, 1136–1144.
21.
SapkotaS, EricksonK, HarveyD, Tomaszewski-FariasSE, OlichneyJM, JohnsonDK, DuggerBN, MungasDM, FletcherE, MaillardP, SeshadriS, SatizabalCL, KautzT, ParentD, TracyRP, MaezawaI, JinLW, DeCarliC (2022) Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume. , e, Alzheimers Dement (Amst)14, 12349.
22.
FletcherE, FilshteinTJ, HarveyD, RenaudA, MungasD, DeCarliC (2018) Staging of amyloid β, t-tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses. Alzheimers Dement (Amst)10, 382–393.
23.
UchidaY, KanH, SakuraiK, HorimotoY, HayashiE, IidaA, OkamuraN, OishiK, MatsukawaN (2022) APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood-brain barrier dysfunction. J Neurol Neurosurg Psychiatry.
24.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
25.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
26.
LuJ, LiD, LiF, ZhouA, WangF, ZuoX, JiaXF, SongH, JiaJ (2011) Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: A population-based study. J Geriatr Psychiatry Neurol24, 184–190.
27.
HughesCP, BergL, DanzigerWL, CobenLA, MartinRL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
28.
YesavageJA, BrinkTL, RoseTL, LumO, HuangV, AdeyM, LeirerVO (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res17, 37–49.
29.
GmitrowiczA, KucharskaA (1994) [Developmental disorders in the fourth edition of the American classification: Diagnostic and statistical manual of mental disorders (DSM IV –optional book)]. Psychiatr Pol28, 509–521.
30.
FolsteinM, AnthonyJC, ParhadI, DuffyB, GruenbergEM (1985) The meaning of cognitive impairment in the elderly. J Am Geriatr Soc33, 228–235.
31.
NasreddineZS, PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
32.
MlinacME, FengMC (2016) Assessment of activities of daily living, self-care, and independence. Arch Clin Neuropsychol31, 506–516.
33.
GuoQ, ZhaoQ, ChenM, DingD, HongZ (2009) A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord23, 253–259.
34.
Tzourio-MazoyerN, LandeauB, PapathanassiouD, CrivelloF, EtardO, DelcroixN, MazoyerB, JoliotM (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage15, 273–289.
35.
YanCG, WangXD, ZuoXN, ZangYF (2016) DPABI: Data processing & analysis for (resting-state) brain imaging. Neuroinformatics14, 339–351.
36.
VergalloA, LemercierP, CavedoE, ListaS, VanmechelenE, De Vos A, ZetterbergH, BlennowK, HabertMO, PotierMC, DuboisB, TeipelS, HampelH (2021) Plasma β-secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimers Dement17, 629–640.
37.
LeeH, CashinAG, LambSE, HopewellS, VansteelandtS, VanderWeeleTJ, MacKinnonDP, MansellG, CollinsGS, GolubRM, McAuleyJH, LocalioAR, van Amelsvoort L, GuallarE, RijnhartJ, GoldsmithK, FairchildAJ, LewisCC, KamperSJ, WilliamsCM, HenschkeN (2021) A guideline for reporting mediation analyses of randomized trials and observational studies: The AGReMA Statement. JAMA326, 1045–1056.
38.
ZhaoJ, FuY, YasvoinaM, ShaoP, HittB, O’ConnorT, LoganS, MausE, CitronM, BerryR, BinderL, VassarR (2007) Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer’s disease pathogenesis. J Neurosci27, 3639–3649.
39.
KandalepasPC, SadleirKR, EimerWA, ZhaoJ, NicholsonDA, VassarR (2013) The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol126, 329–352.
BaraoS, ZhouL, AdamczukK, VanhoutvinT, van Leuven F, DemedtsD, VijvermanAC, BossuytX, VandenbergheR, De Strooper B (2013) BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res10, 671–678.
DecourtB, SabbaghMN (2011) BACE1 as a potential biomarker for Alzheimer’s disease. J Alzheimers Dis24 Suppl 2, 53–59.
44.
JackCR, Jr., PetersenRC, XuYC, O’BrienPC, WaringSC, TangalosEG, SmithGE, IvnikRJ, ThibodeauSN, KokmenE (1998) Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol43, 303–310.
45.
ShieFS, LeBoeufRC, JinLW (2003) Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport14, 123–129.
46.
ZiontzJ, AdamsJN, HarrisonTM, BakerSL, JagustWJ (2021) Hippocampal connectivity with retrosplenial cortex is linked to neocortical tau accumulation and memory function. J Neurosci41, 8839–8847.
47.
VyhnalekM, NikolaiT, AndelR, NedelskaZ, Rubínova E, MarkovaH, LaczóJ, BezdicekO, SheardovaK, HortJ (2014) Neuropsychological correlates of hippocampal atrophy in memory testing in nondemented older adults, J Alzheimers Dis42 Suppl 3, S81–90.
VilleneuveS, ReedBR, WirthM, HaaseCM, MadisonCM, AyaktaN, MackW, MungasD, ChuiHC, DeCarliC, WeinerMW, JagustWJ (2014) Cortical thickness mediates the effect of β-amyloid on episodic memory. Neurology82, 761–767.
50.
MulderSD, van der FlierWM, VerheijenJH, MulderC, ScheltensP, BlankensteinMA, HackCE, VeerhuisR (2010) BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis20, 253–260.
ButterfieldDA, JohnsonLA (2020) APOE in Alzheimer’s disease and neurodegeneration. Neurobiol Dis139, 104847.
53.
NotkolaIL, SulkavaR, PekkanenJ, ErkinjunttiT, EhnholmC, KivinenP, TuomilehtoJ, NissinenA (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology17, 14–20.
54.
KojroE, GimplG, LammichS, MarzW, FahrenholzF (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A98, 5815–5820.
55.
ChenX, HuiL, GeigerJD (2014) Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer’s disease. J Neurol Neurophysiol5, 236.
56.
TianS, HuangR, GuoD, LinH, WangJ, AnK, WangS (2020) Associations of plasma BACE1 level and BACE1 C786G gene polymorphism with cognitive functions in patients with type 2 diabetes: A cross- sectional study. Curr Alzheimer Res17, 355–364.
57.
CummingsJ, LeeG, NahedP, KambarM, ZhongK, FonsecaJ, TaghvaK (2022) Alzheimer’s disease drug development pipeline: 2022., Alzheimers Dement (N Y)8, e12295.
58.
HampelH, O’BryantSE, MolinuevoJL, ZetterbergH, MastersCL, ListaS, KiddleSJ, BatrlaR, BlennowK (2018) Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nat Rev Neurol14, 639–652.
59.
BarãoS, MoecharsD, LichtenthalerSF, De Strooper B (2016) BACE1 physiological functions may limit its use as therapeutic target for Alzheimer’s disease. Trends Neurosci39, 158–169.
ClarimónJ, BertranpetitJ, CalafellF, BoadaM, TàrragaL, ComasD (2003) Association study between Alzheimer’s disease and genes involved in Abeta biosynthesis, aggregation and degradation: Suggestive results with BACE1. J Neurol250, 956–961.
